Clinical Trials in Brazil / NCT06945978
Recruiting
Observational
Validation of a miRNA Panel to Optimize Treatment Response in Patients With Metastatic Pancreatic Cancer (mirPANC 2)
NCT06945978 · tracked via the Priya Life Science Brazil tracker
Condition(s) studied
Pancreatic CancerMetastasisEpigenetic
Study summary
This study is being conducted to better understand how pancreatic cancer behaves during treatment and how we can improve methods for monitoring disease progression. The research aims to determine whether small molecules present in the blood, called miRNAs, can help doctors assess whether the treatment is working or needs adjustment. With this, we hope to make cancer monitoring less invasive and more precise, allowing patients to receive more personalized and effective treatments.
Eligibility
Inclusion Criteria:
* Patients diagnosed with metastatic PDAC;
* Patients who will start treatment with FOLFIRINOX;
* 18 years or older;
* Who agree to participate in the study by signing the Informed Consent Form;
Exclusion Criteria:
* Patients who have previously undergone chemotherapy, whether neoadjuvant, adjuvant, or any prior first-line treatment;
* Patients who do not meet the minimum criteria to receive the proposed regimen, such as those with hyperbilirubinemia, those who are not candidates due to age or performance status deterioration;
Primary outcome measure(s)
- Response to treatment — After 4 cycle of therapy (each cycle is 15 days)
Response to FOLFIRINOX treatment after 4 cycles of therapy. - Response to treatment — After the 8 cycle of therapy (each cycle is 15 days)
Response to FOLFIRINOX treatment after 8 cycles of therapy.
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| A Beneficência Portuguesa de São Paulo | São Paulo | São Paulo | Recruiting |
Other trials for the same condition
A Study of Zolbetuximab (IMAB362) in Adults With Pancreatic Cancer
Active, not recruiting
Official registry record
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT06945978 on ClinicalTrials.gov ↗ ← All trials in Brazil